Ebronucimab vs Laroprovstat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Ebronucimab

Marketed by Hubei Jumpcan Pharmaceutical and partners

Phase 3 in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Partial signal

NCT05255094 · Phase 3 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. Its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.

Reported efficacy

Percentage change from baseline of serum LDL-C level (At week 12): LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). (met)

Result source: NCT05255094

Laroprovstat

Developed by AstraZeneca

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule
Reliable signal

NCT06173570 · Phase 2 · completed

The study randomized 428 participants to four AZD0780 dose groups or matched placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the regulator-accepted lipid measure LDL cholesterol, and all four AZD0780-versus-placebo comparisons were statistically significant in the favorable direction (p<0.001).

Next expected readout: January 2027 · NCT07000136 (registry estimate)

Reported efficacy

Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo) (met)

Result source: NCT06173570

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEbronucimabLaroprovstat
LDL-C, % change—Not posted · NCT05260411-46.6% vs 4.1%−50.7 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -41.1% vs 4.1% 10 mg · wk 12 · n 84 · Phase 2 · primary NCT06173570
  • -33.8% vs 4.1% 3 mg · wk 12 · n 85 · Phase 2 · primary NCT06173570
  • -31.2% vs 4.1% 1 mg · wk 12 · n 86 · Phase 2 · primary NCT06173570
  • -46.4% vs 3.4% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -40.5% vs 3.4% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -33.4% vs 3.4% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -30.5% vs 3.4% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
Non-HDL-C, % change—Not posted · NCT05260411-41.6% vs 3.5%−45.2 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -41.4% vs 2.9% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -35.1% vs 3.5% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -34.8% vs 2.9% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -29.9% vs 3.5% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -29.4% vs 2.9% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -26.9% vs 3.5% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
  • -26.1% vs 2.9% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
ApoB, % change—Not posted · NCT05260411-37.0% vs 2.9%−39.9 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -36.9% vs 2.4% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -34.3% vs 2.9% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -33.9% vs 2.4% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -25.4% vs 2.9% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -24.5% vs 2.4% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -24.1% vs 2.9% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
  • -23.4% vs 2.4% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
Lp(a), % change—Not posted · NCT05260411-19.4% vs 0%−19.4 vs placebo30 mg · wk 12 · n 76NCT06173570
3 other results
  • -19.6% vs 0% 10 mg · wk 12 · n 81 · Phase 2 · secondary NCT06173570
  • -11.2% vs 0% 3 mg · wk 12 · n 75 · Phase 2 · secondary NCT06173570
  • -7.5% vs 0% 1 mg · wk 12 · n 75 · Phase 2 · secondary NCT06173570
3-point MACE (% with event)—Not posted · NCT05260411—Trial running · NCT06834932

LDL-C, % change

Ebronucimab
—Not posted · NCT05260411
Laroprovstat
-46.6% vs 4.1%−50.7 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -41.1% vs 4.1% 10 mg · wk 12 · n 84 · Phase 2 · primary NCT06173570
  • -33.8% vs 4.1% 3 mg · wk 12 · n 85 · Phase 2 · primary NCT06173570
  • -31.2% vs 4.1% 1 mg · wk 12 · n 86 · Phase 2 · primary NCT06173570
  • -46.4% vs 3.4% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -40.5% vs 3.4% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -33.4% vs 3.4% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -30.5% vs 3.4% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570

Non-HDL-C, % change

Ebronucimab
—Not posted · NCT05260411
Laroprovstat
-41.6% vs 3.5%−45.2 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -41.4% vs 2.9% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -35.1% vs 3.5% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -34.8% vs 2.9% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -29.9% vs 3.5% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -29.4% vs 2.9% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -26.9% vs 3.5% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
  • -26.1% vs 2.9% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570

ApoB, % change

Ebronucimab
—Not posted · NCT05260411
Laroprovstat
-37.0% vs 2.9%−39.9 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -36.9% vs 2.4% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -34.3% vs 2.9% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -33.9% vs 2.4% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -25.4% vs 2.9% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -24.5% vs 2.4% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -24.1% vs 2.9% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
  • -23.4% vs 2.4% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570

Lp(a), % change

Ebronucimab
—Not posted · NCT05260411
Laroprovstat
-19.4% vs 0%−19.4 vs placebo30 mg · wk 12 · n 76NCT06173570
3 other results
  • -19.6% vs 0% 10 mg · wk 12 · n 81 · Phase 2 · secondary NCT06173570
  • -11.2% vs 0% 3 mg · wk 12 · n 75 · Phase 2 · secondary NCT06173570
  • -7.5% vs 0% 1 mg · wk 12 · n 75 · Phase 2 · secondary NCT06173570

3-point MACE (% with event)

Ebronucimab
—Not posted · NCT05260411
Laroprovstat
—Trial running · NCT06834932
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ebronucimab: 0 of 4 rows · Laroprovstat: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEbronucimabLaroprovstat
Dropout rate—
5.9%30 mga
NCT06173570 · Phase 2
show 3 more results
1.2%10 mg
NCT06173570 · Phase 2
4.7%3 mg
NCT06173570 · Phase 2
5.8%1 mg
NCT06173570 · Phase 2
Discontinued due to AEs—
2.4%30 mga
NCT06173570 · Phase 2
show 3 more results
0%10 mg
NCT06173570 · Phase 2
0%3 mg
NCT06173570 · Phase 2
1.2%1 mg
NCT06173570 · Phase 2
Serious AEs—
1.2%30 mga
NCT06173570 · Phase 2
show 3 more results
2.4%10 mg
NCT06173570 · Phase 2
2.4%3 mg
NCT06173570 · Phase 2
2.3%1 mg
NCT06173570 · Phase 2
Most frequent reported AEs—
30 mga
hypertension 3.5% (placebo 5.8%)
NCT06173570 · Phase 2
show 3 more results
10 mg
hypertension 2.4% (placebo 5.8%)
NCT06173570 · Phase 2
3 mg
hypertension 2.4% (placebo 5.8%)
NCT06173570 · Phase 2
1 mg
hypertension 4.7% (placebo 5.8%)
NCT06173570 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ebronucimab

LDL-C -59.13% @ 12wk450 mg Q4W
percent change · % of baseline
No placebo or comparator arm
NCT05255094 · Phase 3 · sponsor-reported, not registry data
show 1 more result
-60.43% @ 12wk150 mg Q2W
NCT05255094 · Phase 3 · sponsor-reported, not registry data

Laroprovstat

LDL-C -46.62% (n=85) vs 4.08% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
-46.41% (n=85) vs 3.39% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
-41.09% (n=84) vs 4.08% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-40.47% (n=84) vs 3.39% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-33.83% (n=85) vs 4.08% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-33.35% (n=85) vs 3.39% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-31.19% (n=86) vs 4.08% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
-30.47% (n=86) vs 3.39% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Total Cholesterol -27.06% (n=85) vs 2.29% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
-26.9% (n=85) vs 1.73% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
-24.84% (n=84) vs 2.29% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-24.54% (n=84) vs 1.73% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-20.09% (n=85) vs 2.29% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-19.8% (n=85) vs 1.73% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-18.93% (n=86) vs 2.29% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
-18.23% (n=86) vs 1.73% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
HDL-C 4.66% (n=85) vs 3.65% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
4.65% (n=85) vs 3.11% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
1.97% (n=84) vs 3.65% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
2.17% (n=84) vs 3.11% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
4.03% (n=85) vs 3.65% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
3.66% (n=85) vs 3.11% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
0.12% (n=86) vs 3.65% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
0.8% (n=86) vs 3.11% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Triglycerides -0.44% (n=85) vs 9.56% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
-0.83% (n=85) vs 9.04% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
1.93% (n=84) vs 9.56% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
1.72% (n=84) vs 9.04% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
2.9% (n=85) vs 9.56% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
2.17% (n=85) vs 9.04% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
3.06% (n=86) vs 9.56% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
2.81% (n=86) vs 9.04% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Non-HDL-C -41.65% (n=85) vs 3.53% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
-41.35% (n=85) vs 2.86% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
-35.13% (n=84) vs 3.53% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-34.77% (n=84) vs 2.86% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-29.86% (n=85) vs 3.53% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-29.42% (n=85) vs 2.86% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-26.85% (n=86) vs 3.53% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
-26.13% (n=86) vs 2.86% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
VLDL-C 0.46% (n=85) vs 7.19% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
0.42% (n=85) vs 6.74% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
2.21% (n=84) vs 7.19% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
1.77% (n=84) vs 6.74% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
4.02% (n=85) vs 7.19% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
2.67% (n=85) vs 6.74% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
1.13% (n=86) vs 7.19% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
0.81% (n=86) vs 6.74% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Apo A1 5.72% (n=85) vs 4.46% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
5.55% (n=85) vs 3.82% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
3.61% (n=84) vs 4.46% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
3.79% (n=84) vs 3.82% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
3.25% (n=85) vs 4.46% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
2.89% (n=85) vs 3.82% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
1.67% (n=86) vs 4.46% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
2.52% (n=86) vs 3.82% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Apo B -36.95% (n=85) vs 2.92% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
-36.86% (n=85) vs 2.44% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
-34.33% (n=84) vs 2.92% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-33.85% (n=84) vs 2.44% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-25.39% (n=85) vs 2.92% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-24.53% (n=85) vs 2.44% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-24.08% (n=86) vs 2.92% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
-23.35% (n=86) vs 2.44% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Lp(a -19.43% (n=76) vs 0% (n=78) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 3 more results
-19.57% (n=81) vs 0% (n=78) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-11.16% (n=75) vs 0% (n=78) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-7.48% (n=75) vs 0% (n=78) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Remnant Cholesterol -18.31% (n=77) vs -5% (n=80) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 3 more results
-22.95% (n=79) vs -5% (n=80) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-8.33% (n=75) vs -5% (n=80) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-9.09% (n=75) vs -5% (n=80) placebo @ 12wk1 mg
NCT06173570 · Phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ebronucimab's landscape · Laroprovstat's landscape